<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03964792</url>
  </required_header>
  <id_info>
    <org_study_id>P170006J</org_study_id>
    <nct_id>NCT03964792</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene in Patients With Sickle Cell Disease (DREPAGLOBE)</brief_title>
  <acronym>DREPAGLOBE</acronym>
  <official_title>A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients With Sickle Cell Disease (SCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the
      Sickle Cell disease by Transplantation of an Autologous CD34+ enriched cell fraction that
      contains CD34+ cells transduced ex vivo with the GLOBE1 lentiviral vector expressing the βAS3
      globin gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients with Sickle Cell
      Disease (SCD)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2019</start_date>
  <completion_date type="Anticipated">November 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of transplant related mortality</measure>
    <time_frame>up to 100 days post treatment</time_frame>
    <description>To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of the need for rescue autologous bone marrow transplant</measure>
    <time_frame>up to 100 days post treatment</time_frame>
    <description>To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of AEs post transplant transplant</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>Based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of vector-derived Replication competent lentivirus (RCL)</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically detectable malignancy and/or abnormal clonal dominance assessed as related to study treatment</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the procedure safety.It will be evaluated by vector insertion site analysis (VISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of neutrophil</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of platelet</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the efficacy. It will be quantified by High performance liquid chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage HbAS3</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>To evaluate the efficacy. It will be quantified by High performance liquid chromatography It will be quantified by High performance liquid chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>based on the United States national Cancer Institute Common Terminology Criteria for Adverse Events v4.03 To evaluate the long -term safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of RCL (Replication competent lentivirus)</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>To evaluate the long -term safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of clinically detectable malignancy or abnormal clonal dominance assessed as related to study treatment</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>To evaluate the long -term safety. It will be evaluated by vector insertion site analysis (VISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein expression through percentage of anti-sickling Hb</measure>
    <time_frame>24 months post-transplant</time_frame>
    <description>To evaluate the long -term efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>DREPAGLOBE drug product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The DREPAGLOBE is a genetically modified cell therapy product that consists of autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs) that are enriched in CD34+ cells which have been transduced ex vivo with the lentiviral vector, GLOBE1, expressing an anti-sickling β-globin protein (AS3) containing three amino acid substitutions in the wild-type β-globin gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DREPAGLOBE drug product</intervention_name>
    <description>Each patient will receive a single IV infusion of DREPAGLOBE drug product</description>
    <arm_group_label>DREPAGLOBE drug product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age 5 - 35 years

          -  Diagnosis of HbSS or S-beta zero thalassemia by Hb electrophoresis or genetic
             analysis.

          -  Clinical history or ongoing evidence of severe sickle cell anemia with one OR more of
             the following clinical complications demonstrating disease severity:

               -  At least 3 vaso occlusive crises requiring hospitalization, under hydroxyurea or
                  transfusion, within 2 years prior to enrollment

               -  One severe acute chest syndrome (ACS) hospitalized in intensive care unit

               -  At least 2 episodes of ACS within the prior 3 years), including one under HU.

               -  Acute priapism (at least 2 episodes &gt; 3h in the preceding year or in the year
                  prior to the start of a regular transfusion program), OR stuttering priapism ≥ 1
                  by week under sickle cell treatment (HU, transfusion or phlebotomy).

               -  Cerebral vasculopathy confirmed by MRA (magnetic resonance angiography) without
                  Moya-moya

               -  Presence of sickle cell cardiomyopathy documented by Doppler echocardiography
                  (left ventricular ejection fraction (LVEF) &lt;55% AND tricuspid regurgitation
                  velocity &gt;2.5m/s on cardiac echocardiograph),

               -  Tricuspid regurgitation velocity &gt;2.8m/s on cardiac echocardiograph without
                  pulmonary hypertension confirmed by right heart catheterization (mPAP&lt;25mmHg)

          -  Failed hydroxyurea (HU) therapy, were unable to tolerate HU therapy, or, if 18 years
             of age or older, have actively made the choice to not take the recommended daily HU
             regimen. Inadequate clinical response to HU, defined as any one of the following
             outcomes, while on HU for at least 3 months: 2 or more acute sickle pain crises
             requiring hospitalization, no rise in Hb &gt;1.5 gm/dl from pre-HU baseline or requires
             transfusion to maintain Hb &gt; 6.0 gm/dL, had an episode of ACS despite adequate
             supportive care measures.

          -  Karnovsky/Lansky performance score ≥ 60%

          -  Sexually active patients must be willing to use an acceptable method of double-barrier
             contraception for at least 12 months post-infusion (beyond 12 months at the discretion
             of the investigator)

        Exclusion Criteria:

          -  Existence of a matched sibling donor

          -  Patients who have started new treatment for SCD within 6months of enrollment

          -  Hematologic evaluation: Leukopenia (WBC &lt; 3000 µL) ( en cours) or neutropenia (ANC &lt;
             1000 µL) or thrombocytopenia (platelet count &lt; 100,000 µL) (not due to an
             erythropheresis procedure)

          -  PT/INR or PTT &gt; 1.5 times upper limit of normal (ULN) or clinically significant
             bleeding disorder

          -  Evaluations within 6 months prior to screening visit:

          -  ALT or AST &gt; 3 times ULN

          -  Liver Cirrhosis suspicion on echography, CT scan or MRI AND confirmed by histology

          -  Cardiac evaluation: LVEF &lt; 40% by cardiac echocardiogram or by MUGA scan

          -  Stroke with significant CNS sequelae i.e., Rankin &gt; 2

          -  Lung interstitial infiltrate AND Forced Vital Capacity less than 70% AND DLCO less
             than 60% at steady state

          -  Confirmed pulmonary hypertension defined by a right heart catheterization
             (PAPm&gt;25mmHg). Right heart catheterization is required if tricuspid regurgitation
             velocity &gt;2.8m/s on cardiac echocardiograph OR &gt;2.5m/s with an abnormal Brain
             Natriuretic Peptide dosage or an important decrease in transcutaneous Hb O2 saturation
             during the 6 minutes walk test.

          -  Seropositivity for HIV (Human Immunodeficiency Virus), HCV (Hepatitis C Virus), HTLV-1
             (Human T-Lymphotropic Virus), or active Hepatitis B Virus, or active infection by CMV
             or parvovirus B19, based on positive blood PCR.

          -  Pregnancy or breastfeeding in a postpartum female

          -  Any current cancer or prior history of a malignant disease, with the exception of
             curatively treated non-melanoma skin cancer

          -  Immediate family member with an established or suspected Familial Cancer Syndrome

          -  Diagnosis of significant psychiatric disorder of the subject that could seriously
             impeded the ability to participate in the study

          -  Patients who failed previous HSCT and are severely ill

          -  Any clinically significant active infection

          -  Participation in another clinical study with an investigational drug within 30 days of
             screening

          -  Any condition, based on perspective of the medical monitor and treating investigator,
             which may lead to increased safety risk or inability to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo BARTULOCCI, MD &amp; PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of internal medicine, Henri-Mondor Hospital, Creteil, France.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina CAVAZZANA, MD &amp; PhD</last_name>
    <phone>+33 144495068</phone>
    <email>m.cavazzana@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie JOLAINE, Manager</last_name>
    <phone>+33 1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Biotherapy, Necker-Enfants Malades Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marina CAVAZZANA, MD &amp; PhD</last_name>
      <phone>+33 144495068</phone>
      <email>m.cavazzana@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

